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Abstract
Background: Preclinical studies in breast cancer models showed that BRCA1 or BRCA2 deficient cell lines, when
compared to BRCA proficient cell lines, are extremely sensitive to PARP1 inhibition. When combining the PARP1
inhibitor olaparib with cisplatin in a BRCA1-mutated breast cancer mouse model, the combination induced a larger
response than either of the two compounds alone. Several clinical studies have investigated single agent therapy
or combinations of both drugs, but no randomized clinical evidence exists for the superiority of carboplatin-olaparib
versus standard of care therapy in patients with BRCA1- or BRCA2–mutated metastatic breast cancer.
Methods/design: This investigator-initiated study contains two parts. Part 1 is a traditional 3 + 3 dose escalation study
of the carboplatin-olaparib combination followed by olaparib monotherapy. The carboplatin dose will be escalated
from area under the curve (AUC) 3 to AUC 4 with an olaparib dose of 25 mg BID. Olaparib is subsequently escalated to
50, 75, and 100 mg BID until >1/6 of patients develop dose-limiting toxicity (DLT). The dose level below will be the
maximum tolerable dose (MTD). It is expected that 15–20 patients are needed in Part I.
In Part 2 BRCA1- or BRCA2-mutated HER2-negative breast cancer patients will be randomized between standard
capecitabine 1250 mg/m2 BID day 1–14 q day 22, versus 2 cycles carboplatin-olaparib followed by olaparib
monotherapy 300 mg BID. In total 104 events in 110 patients need to be observed to detect a 75 % clinically
meaningful improvement in progression-free survival (PFS), from a median of 4 months (control) to 7 months
(experimental) assuming a 2-year accrual and ≥6 months of follow-up with 80 % power (5 %, two-sided significance
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level). After progression on first line treatment, patients will receive physician’s best choice of paclitaxel, vinorelbine,
eribulin, or capecitabine (experimental arm only) at standard dose. A compassionate use program of olaparib
is available for patients in the standard arm after progression on second line treatment.
Discussion: Results might be pivotal for registration of olaparib as standard first line treatment in advanced
BRCA1- or BRCA2-mutated breast cancer.
Trial registration: ClinicalTrials.gov identifier: NCT02418624. Registered on 9 March 2015. EudraCT number:
2013-005590-41. Registered on 15 October 2014. Protocol version 3.0.
Keywords: Breast cancer, Metastatic, BRCA1, BRCA2, Homologous recombination deficiency, PARP inhibitors,
Olaparib, Carboplatin, Capecitabine
Background
Patients harboring inactivating mutations in BRCA1
or BRCA2 are at an increased risk of developing
breast cancer [1]. It has become clear that these
genes are important in error-free DNA double strand
break (DSB) repair via homologous recombination.
Loss of the second allele inactivates error-free repair
of DNA DSBs. Error-prone mechanisms of repair sub-
stitute and repair these DNA lesions, resulting in
either aberrations in the genome or cell death when
crisis cannot be resolved [2–8]. Targeting the defect-
ive repair with DNA double strand break-inducing
agents like platinum compounds might be beneficial
for BRCA1 or BRCA2 mutation carriers with breast
cancer. Single agent carboplatin has been extensively
investigated, from fundamental studies to clinical
studies, e.g., the Triple Negative Breast Cancer trial
(TNT, NCT00532727) enriched for patients with cancers
harboring BRCA mutations. In the TNT trial, patients
with advanced triple negative (TN) breast cancer were
randomized to six 3-weekly cycles of carboplatin area
under the curve (AUC) 6 or six 3-weekly cycles of doce-
taxel 100 mg/m2 in first or second line. The TNT trial
showed that patients with a BRCA1 or BRCA2 mutation
derive benefit from carboplatin over docetaxel [9]. How-
ever, carboplatin is not a registered choice for this sub-
group at the moment.
Another way to target defective homologous recom-
bination is by inhibition of poly(ADP)ribose polymerase-
1 (PARP1) [10–12]. BRCA1 or BRCA2 deficient cells
and conditional mouse tumors proved to be extremely
sensitive to PARP1 inhibition in clonogenic survival as-
says, whereas BRCA proficient cells were not sensitive
[10–12]. PARP1 inhibition may result in cell kill through
different mechanisms: (1) the inhibition of single strand
break repair resulting in single strand breaks evolving
into DSBs which cannot be repaired error-free in the ab-
sence of BRCA, (2) trapping of PARP1 on damaged
DNA, (3) impairment of BRCA1 recruitment, or (4) the
activation of non-homologous end joining [13–17].
Olaparib is a PARP1 inhibitor that has recently been
approved by the European Medicines Agency (EMA)
as maintenance therapy for BRCA-mutated advanced
high-grade serous ovarian cancers after response to
platinum-based chemotherapy. The FDA approved
olaparib for the treatment of advanced BRCA-mutated
ovarian cancers previously treated with ≥3 lines of
chemotherapy [18, 19].
Several phase I and II clinical trials have tested ola-
parib monotherapy as capsule formulation in (breast)
cancer populations carrying a BRCA1 or BRCA2 mu-
tation or populations enriched for mutation carriers
[20–23]. Patients were required to take 16 olaparib
capsules of 50 mg each day to reach the 400-mg BID
monotherapy dose. Therefore, a tablet formulation
was developed. The capsule and tablet formulations
are not bio-equivalent. The oral pharmacokinetics of
olaparib as capsule formulation was nonlinear. The tablet
formulation was tested and found safe. Four hundred mg
BID olaparib capsules are dose equivalent to 2 tablets of
150 mg olaparib (300 mg BID) [24–26].
One study enrolled 60 patients in a phase I trial. The
maximum tolerable dose (MTD) of olaparib as capsule
formulation was found to be 400 mg BID. Maximum
PARP1 inhibition was reached at doses of 100 mg. In
total 12/19 BRCA1 or BRCA2 mutation carriers derived
clinical benefit [21]. In a follow-up study, 81 patients
were screened for BRCA1 or BRCA2 mutations, and 54
of them were enrolled into receiving 100 mg BID or
400 mg BID, respectively. The primary outcome was ob-
jective response rate (ORR) according to the Response
Evaluation Criteria In Solid Tumors (RECIST). Intra-
patient dose escalation was allowed since interim ana-
lyses showed that responses in the 400 mg cohort were
more durable. Despite maximum PARP1 inhibition at
100 mg BID, the median progression-free survival was
5.7 months in the 400 mg BID cohort versus 3.8 months
in the 100 mg BID cohort [22]. Adverse events occurred
in up to 81 % of patients and were mostly mild, grade 1
or 2 according to Common Terminology Criteria for
Adverse Events (CTCAE) and consisted of nausea,
vomiting, fatigue, and myelosuppression [21–23].
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As mentioned, both traditional platinum drugs and
olaparib target a defect in homologous recombination,
platinum agents by directly inducing toxic DNA lesions
and olaparib by (a combination of ) inhibiting backup
repair pathways, PARP1 trapping, impairing BRCA1, or
activating non-homologous end joining (NHEJ) with a
synthetic lethal result. Combining the two may there-
fore induce extra benefit for patients. In fact, in BRCA2
deficient cells it was found that the combination of ola-
parib and cisplatin was synergistic [27]. Furthermore,
the combination of cisplatin with olaparib was investi-
gated in a BRCA1-associated breast cancer mouse
model. In this model combination treatment induced
more durable responses compared to either of the com-
pounds alone [12]. The strategy of combining multiple
drugs has potentially a more than additive effect.
Although the combination is limited by bone marrow
toxicity, it may be that the combination of two types of
damage is more effective than overloading a cell with
only one type of damage mechanism. Furthermore,
sensitization to olaparib may occur, for example, due to
DNA damage, inducing PARP1 expression [16, 17, 28].
The non-randomized open-label phase I study
NCT00516724 investigated combinations of olaparib
with carboplatin and/or paclitaxel in advanced breast
and ovarian cancer. A final report has not been pub-
lished yet, but pharmacokinetic (PK) and toxicity infor-
mation was available to guide the design of the current
trial. Many cohorts in this trial demonstrated dose-
limiting toxicities early in the six cycles of combination
treatment and required dose modifications. These find-
ings are similar to other trials, in which the selected
schedule did not contain continuous dosing of olaparib
[29, 30]. Therefore, cohorts without dose-limiting tox-
icity or treatment delays in the first two cycles were
deemed feasible regimens for combination therapy.
These feasible dose levels comprised carboplatin AUC 4
in combination with either olaparib 50 mg BID plus pac-
litaxel 90 mg/m2 or olaparib 50 mg BID plus paclitaxel
75 mg/m2 or olaparib 200 mg BID on days 1–10 plus
paclitaxel 175 mg/m2. The aforementioned regimens
contained olaparib capsules and all regimens contained
paclitaxel. For these two reasons a brief dose-finding
study of carboplatin in combination with olaparib tablets
is required. In an analysis of anti-tumor activity, cohorts
were grouped by olaparib formulation and drug combin-
ation. In these cohorts response rates determined as
stable disease (SD) >2 months, partial response (PR), or
complete response (CR) were 38 % (16/42) among pa-
tients [31]. Despite the limitations of a single arm trial
testing six cycles of combination therapy, extrapolating
this to a new study with modified and probably im-
proved drug formulation and combination treatment (no
paclitaxel and fewer combination cycles) seems feasible,
since doses are exerting effects both in inducing
toxicity and preliminary responses. After completing
combination therapy, patients remained on olaparib
monotherapy, sometimes for very long periods of time
[32]. One may wonder whether combining carboplatin
and olaparib only in the first two cycles may be insuffi-
cient to yield benefit. However, the response and tox-
icity observed in the NCT00516724 trial suggest that
the proposed dose escalation scheme will not lead to
subtherapeutic dosing despite incorporating carboplatin
only in the first two cycles. For the monotherapy dose,
we follow previous studies that established 300 mg BID
as being safe and efficacious [24–26].
Currently no specific guidelines for systemic therapy
in the metastatic setting are available for BRCA1- or
BRCA2-mutated breast cancers. Capecitabine is regis-
tered for the indication of metastatic breast cancer if
patients have been pretreated with anthracyclines and
a taxane and does not specifically target a defect in
homologous recombination [33, 34].
No randomized comparative evidence supporting
olaparib monotherapy or combination therapy in meta-
static breast cancer is available, but sufficient evidence
is available to conduct such a trial. It is considered of
importance to swiftly determine whether a BRCA1 or
BRCA2 mutation targeting regimen has a positive bene-
fit/risk ratio. Therefore, we initiated this combined
phase I/randomized phase II controlled trial.
Methods/design
A description of this manuscript according to the
SPIRIT guidelines is presented in Additional file 1. This
investigator-initiated study consists of two parts. Dur-
ing Part 1, a traditional 3 + 3 dose escalation study is
performed to determine the MTD of two cycles
carboplatin-olaparib followed by olaparib. This is re-
quired due to a change in formulation from olaparib
capsules to olaparib tablets with improved pharmaco-
logical characteristics. After the MTD is established in
Part 1, Part 2 will be initiated. Part 2 is a phase II ran-
domized, multicenter, open-label trial, comparing the
progression-free survival on first line treatment (PFS1)
of two cycles of carboplatin-olaparib followed by
olaparib monotherapy to capecitabine monotherapy.
After progression on first line treatment, patients will
receive physician’s best choice of paclitaxel, vinorelbine,
or eribulin, and in the case of carboplatin-olaparib
treated patients, the same choice complemented with
capecitabine. A schematic description of the trial is
shown in Figs. 1 and 2. A rollover protocol is in place
for patients who were not randomized to olaparib in
first line to allow them access to olaparib monotherapy
as third line treatment. Centers participating in Part 2
of the study are currently being recruited.
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Objectives
The primary objective of Part 1 is to determine the
MTD of two cycles carboplatin-olaparib and one cycle
olaparib monotherapy at standard dose. The MTD is de-
fined as the dose level below the dose level at which >1/6
of patients experience a dose-limiting toxicity (DLT). The
secondary objectives are to investigate the systemic
exposure of the olaparib tablet formulation, the pharma-
codynamics (PD) of olaparib, and the ORR of carboplatin
and olaparib according to RECIST.
In Part 2 the primary objective is to compare the PFS1
of two cycles olaparib-carboplatin followed by olaparib
to capecitabine. Secondary objectives are to compare the
ORR, the progression-free survival on second line
Fig. 1 Schematic representation of the study. In Part 1 patients with advanced disease will be enrolled to be administered carboplatin
and olaparib in two 3-weekly cycles followed by olaparib monotherapy until dose limiting toxicity or progressive disease. The maximum
tolerable dose will be determined
Fig. 2 Patients with BRCA1- or BRCA2-mutated HER2-negative, advanced breast cancer will be randomized to carboplatin-olaparib (based on the
Part 1 results) or capecitabine. After progression on first line, patients will be administered physician’s best choice out of capecitabine, paclitaxel,
vinorelbine, or eribulin to assess progression-free survival on second line treatment. For patients who were not randomized to olaparib, a rollover
protocol is available for third line treatment in the advanced setting
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treatment (PFS2), and overall survival with either two
cycles of olaparib-carboplatin followed by olaparib or
capecitabine as first line and to determine treatment
safety in first and second lines. In both Parts 1 and 2
additional tissue and blood will be collected for explora-
tory biomarker analyses.
Inclusion criteria
Patients are eligible for this study if they are ≥18 years
old, have histological or cytological proven metastatic
cancer, with a life expectancy ≥3 months, a World
Health Organization (WHO) performance status of 0,
1, or 2, and a negative pregnancy test. Minimal ac-
ceptable safety laboratory values include ANC ≥1.5 ×
109/L, hemoglobin ≥6.2 mM (with no transfusions in
the last 28 days), platelet count ≥100 × 109/L, serum
bilirubin ≤1.5 × upper limit of normal (ULN) (or <3 ×
ULN in case of known Gilbert’s syndrome), ASAT
and ALAT 2.5 × ULN (or <5 × ULN in case of liver
metastasis), and serum creatinine ≤1.5 × ULN or cre-
atinine clearance ≥50 mL/min (by the Cockcroft-
Gault formula). Patients should be able and willing to
give informed consent.
In Part 1, all patients with tumors who may benefit
from carboplatin-olaparib therapy and who did not
receive more than one line of systemic chemotherapy
in the advanced setting and any line of hormonal
therapy for advanced disease may be included. Prior
(neo-)adjuvant chemotherapy is accepted and does
not count as one line, because it was administered
for early stage disease. The tumor must be evaluable
according to RECIST 1.1. Patients must consent to
undergo blood sampling for pharmacokinetics and
pharmacodynamics analyses.
In Part 2, patients must have BRCA1- or BRCA2-mu-
tated HER2-negative breast cancer. Pretreatment should
consist of an anthracycline and taxane in the (neo-)adju-
vant setting (unless not indicated) following the label for
capecitabine monotherapy in the metastatic setting but
without systemic chemotherapy pretreatment for ad-
vanced disease and with maximally two lines of hormo-
nal therapy pretreatment in the advanced setting. The
tumor must be measurable according to RECIST 1.1.
Exclusion criteria
Patients are excluded from this study if they are
pregnant or breastfeeding, use unreliable contracep-
tive methods, are treated with cytochrome P450 3A4
(CYP3A4) inducers or inhibitors, or previously re-
ceived a PARP1 inhibitor or high-dose alkylating
agent. Radiotherapy and treatment with investiga-
tional drugs are prohibited within 28 days prior to
receiving the first dose of investigational treatment;
exceptions are 1 × 8 Gray (Gy) for pain palliation and
standard (neo-)adjuvant chemo-, hormonal- and im-
munotherapy. Then 7- and 21-day intervals should
be maintained, respectively. Other conditions exclud-
ing a patient from participating in this part of the
study are uncontrolled infectious diseases, known
human immunodeficiency virus (HIV)-1 or −2 infec-
tions, active hepatitis B or C, myocardial infarction
(<6 months) or unstable angina, myelodysplastic syn-
drome, acute myeloid leukemia, symptomatic brain
metastases, leptomeningeal metastases, or any other
medical condition that interferes with study procedures or
compliance and/or jeopardizes safe treatment.
In Part 1 patients are excluded if they previously re-
ceived carboplatin, unless no progression on carboplatin
was observed during earlier treatment and the last car-
boplatin administration was longer than 6 months ago.
In Part 2 patients are excluded if they are dihydro-
pyrimidine dehydrogenase (DPD) deficient, received
treatment for advanced disease with non-hormonal
anticancer therapy or >2 lines of endocrine therapy,
or were pretreated with capecitabine. Pretreatment
should include an anthracycline and taxane in the
(neo-)adjuvant setting (unless not indicated) following
the label for capecitabine monotherapy in the meta-
static setting.
Interventions
In Part 1, patients will receive two cycles olaparib-
carboplatin followed by olaparib monotherapy. Treat-
ment cycles will be 21 days with the exception of cycle
1, which contains a day 0 for olaparib PK measurements.
Carboplatin will be administered intravenously on day 1
of cycles 1 and 2. A single oral dose of olaparib is ad-
ministered on day 0 and 1 of cycle 1; afterwards olaparib
administration will be twice daily. After cycle 2 olaparib
monotherapy is given at 300 mg BID until progression
or unacceptable treatment-related toxicity occurs. Pa-
tients will be screened for baseline inclusion criteria, and
after informed consent has been received, baseline safety
measurements will be obtained. Subsequently, patients
will be followed up with hospital visits for safety assess-
ment comprising recording of medical history, and phys-
ical examination and laboratory testing every week in
cycles 1 and 2, every cycle in cycles 3 and 4, and every
two cycles from cycle 5 onwards, unless otherwise indi-
cated. Tumor assessment by RECIST will be performed
every two cycles. PK/PD measurements are taken in
cycle 1. Extra blood and tissue samples are collected if
informed consent is obtained before and after treatment.
Dose escalation is performed according to a traditional
3 + 3 design. The carboplatin dose will be escalated in
one step from AUC 3 to AUC 4 with a constant olaparib
dose of 25 mg BID. Olaparib is then escalated to 50, 75,
and 100 mg BID until >1/6 patients develop a DLT; the
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previous safe dose level will be determined as the MTD
and is used as the treatment schedule in Part 2. In Part
2 two cycles carboplatin-olaparib followed by olaparib
monotherapy (experimental arm), dosed according to
the study results of Part 1, are compared to registered
standard of care capecitabine (1250 mg/m2 BID d 1–14
in 21-day cycles, according to the label). After progres-
sion, patients will receive physician’s choice of intraven-
ously delivered (IV) eribulin (1.23 mg/m2 d1,8/21,
equivalent to 1.4 mg/m2 of eribulin mesylate), vinorelbine
(IV) (25 mg/m2 q 1wk), paclitaxel (IV) (80 mg/m2 q 1wk),
or capecitabine (if randomized to carboplatin-olaparib as
first line treatment), drugs registered for second line treat-
ment of metastatic breast cancer. For patients randomized
to the standard arm, olaparib will be available as third line
treatment at time of disease progression.
Patients will be screened for baseline inclusion criteria
and, after signing informed consent, baseline safety mea-
surements will be obtained. Subsequently, patients will
be followed with hospital visits for safety assessment
comprising medical history taking, physical examination,
and laboratory testing every cycle from cycle 1 until 4,
and minimally every two cycles from cycle 5 onwards,
unless more visits are medically indicated. Tumor as-
sessment by RECIST will be performed every two cycles.
Dose modifications
Dose modifications are allowed when toxicity CTCAE
grade >2 (or intolerable grade 2, despite supportive care)
has resolved to grade <2. During carboplatin-olaparib
combination therapy the carboplatin dose will not be
modified. The olaparib dose may be modified in steps of
25 mg following the inversed dose escalation scheme to
a minimum of 25 mg BID. For the first toxicity develop-
ing after the second cycle of carboplatin, the olaparib
dose does not have to be modified and treatment con-
tinues when the toxicity has resolved. However, if a sec-
ond toxicity develops after the second carboplatin dose,
the dose of olaparib must be modified. Patients who de-
velop toxicity while receiving olaparib monotherapy
300 mg BID can resume treatment at 250 mg BID and
subsequently 200 mg BID once adequately recovered.
Dose modifications for capecitabine [34], eribulin [35],
paclitaxel [36], and vinorelbine [37] are allowed accord-
ing to prespecified steps that follow the label.
Pharmacokinetics (PK) and pharmacodynamics (PD)
Blood samples for olaparib and/or carboplatin PK will
be drawn in Part 1 cycle 1 to capture the single agent,
single-dose olaparib PK curve and the PK curves of
olaparib and carboplatin in combination treatment. The
amount of PARP1 inhibition will be measured in periph-
eral blood mononuclear cells (PBMCs) before and dur-
ing olaparib treatment.
Concomitant treatment
Anti-emetic treatment will be administered before
and following the administration of carboplatin, and if
necessary, with erubilin, paclitaxel, and vinorelbine.
Patients receiving paclitaxel should be pretreated to
prevent allergic reactions. Supportive care and other
medication may be given at the discretion of the in-
vestigator(s) and according to good clinical practice.
Administration of granulocyte colony-stimulating factor
(GCSF) is allowed, but not during the first treatment
cycle. One time 8 Gy palliative radiation at focal sites (pre-
ceded and followed by a 3-day wash-out period) and bone
targeting agents for the treatment of bone metastases are
allowed. CYP3A4 inhibitors or inducers are not allowed in
Part 1 and not advised in Part 2. CYP2C8 inhibitors or in-
ducers are not advised in Part 2.
Safety assessments/participant timeline
Measurements used to evaluate safety will include as-
sessment of signs and symptoms/adverse events, phys-
ical examination, performance status, blood pressure
and heart rate measurements, clinical laboratory test-
ing (hematology, clinical chemistry, and urinalysis),
and 12-lead electrocardiography (ECG) monitoring.
Patients are evaluable for safety if they received car-
boplatin intravenously and a dose of olaparib.
Statistics: sample size
For Part 1 no sample size calculation has been per-
formed as statistical analyses will be descriptive in na-
ture. From previous trials it is estimated that 15–20
patients are needed to establish the MTD. In Part 2,
based on expert opinion, the sample size was calculated
using the following parameters: median PFS for the con-
trol group of 4 months and considering 3 months a
worthwhile improvement (hazard ratio of 1.75 under the
alternative hypothesis). Further, choosing a two-sided type
I error of 0.05, a total of 104 events need to be observed
guaranteeing a power of 80 %. Assuming a constant ac-
crual over 2 years and another 6 months of follow-up after
the last patient entered (1:1 randomization), 110 patients
need to be enrolled. An interim analysis is included
allowing for early stopping. The spending function se-
lected is O’Brien-Fleming for the upper bound (effi-
cacy) and the Hwang-Shih-DeCani spending function
with parameter −1 for the non-binding lower bound for
futility [38]. Sample size calculations were performed
using the gsDesign package in R [39]. Regarding the as-
sumptions on survival, these are based on a mostly
triple negative population, due to BRCA1-mutated can-
cers, and a 4–5 month expected benefit of capecitabine
depending on the baseline characteristics, with a re-
ported smaller time to progression of triple negative pa-
tients [40–44]. Patients will be stratified by treating
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center and by hormone receptor status. Given the as-
sumptions, it is expected that the interim analysis oc-
curs after approximately 16 months and the final
analysis after 30 months. If these assumptions are not
met during the trial, the optimal course of adjustment
will be decided in collaboration with an independent
Data and Safety Monitoring Board. No sample size cal-
culation was performed for second line treatment.
Statistics: methods
In Part 1 the baseline characteristics of the study
population will be described according to common
reporting standards (CONSORT 2010 guidelines [45]).
Patients are considered evaluable for PK analyses if
they underwent PK blood sampling during cycle 1.
The pharmacokinetics will be determined using non-
compartmental methods. The mean, median, coefficient
of variation, and range of the following carboplatin and
olaparib parameters will be calculated: time to maximal
plasma concentration (tmax), maximum plasma concentra-
tion (Cmax), area under the time versus concentration
curve from zero to the last data point (AUC0-t), area under
the time versus concentration curve from zero to infinity
(AUCinf), half-life (t1/2), mean residence time (MRT), vol-
ume of distribution (Vdd), and clearance (Cl). To compare
the AUC of capsules obtained from previous studies to
the tablet AUC obtained in this study, the ratio of
log(AUC-tablet)/log(AUC-capsule) should be between 0.8
and 1.25. Inhibition of PAR will be measured with a PAR
activation assay on PBMCs and will be presented as the
percentage of activation after olaparib treatment com-
pared to activation before olaparib treatment. A final de-
scriptive analysis for response, based on RECIST 1.1, will
be done when the last patient has completed the follow-
up visit at end of treatment.
In Part 2 baseline characteristics of the study popu-
lation will be described according to common report-
ing standards (CONSORT 2010 guidelines [45]). PFS1
between the experimental and control arms will be
assessed on the intention-to-treat population using
the Kaplan-Meier survival estimate and log rank test.
A Cox proportional hazards model is used to assess
treatment effect size and adjust for confounding fac-
tors. The data cut-off date will be when 104 events
have been observed. Patients will be followed up to
collect additional survival and safety data for PFS2, and
updated safety and efficacy analyses will be performed.
Logistics and administrative arrangements
REVIVAL was approved by the accredited Medical Ethics
Committee of the Netherlands Cancer Institute - Antoni
van Leeuwenhoek Hospital (NKI-AVL) on 10 February
2015. The study protocol follows the principles of the
Declaration of Helsinki and the Medical Research
Involving Human Subjects Act (WMO), and it is compli-
ant to ICH-GCP.
The NKI-AVL is the coordinating center. Part 1 is a
mono-center study; for Part 2 extra centers are recruited
(inter)nationally. The NKI-AVL Trial Office is the data
center for the entire study. The NKI-AVL pharmacy is
responsible for drug distribution and monitoring.
Patients are registered and allocated to a dose level or
randomized to a treatment arm by the NKI-AVL trial of-
fice after signed informed consent is obtained. Patient
data will be collected as described in the follow-up tables
on case report forms according to the data management
plan and checked according to the data monitoring and
data validation plan. A statistical analysis plan will be
used during data analysis. Toxicity data will be collected
and graded according to CTCAE criteria and will be re-
ported following national law. Response data will be col-
lected and scored according to RECIST criteria. Patients
will remain on treatment until progression or unaccept-
able toxicity. Procedures for dropout due to other rea-
sons and patient replacement are in place.
Discussion
Currently, BRCA1 or BRCA2 mutation carriers with
breast cancer do not receive specific treatment targeting
the defect in their tumor, despite strong preclinical and
promising clinical evidence.
This study aims to provide evidence for a clinically
meaningful improvement of the experimental regimen
over standard of care chemotherapy for metastatic
BRCA1- or BRCA2-mutated breast cancer. In choosing
the experimental and control regimens, several choices
had to be made. Carboplatin and olaparib share
hematological toxicity, which is the main limiting factor
in combination treatment. Preliminary evidence suggests
that this combination cannot be administered for more
than two cycles without treatment delays or unaccept-
able toxicity. The expected dose level contains effica-
cious doses of olaparib and carboplatin in a therapeutic
range. Combining two modes of tumor cell killing may
induce synergy requiring lower doses than single agent
therapy [27]. The control arm treatments are all regis-
tered chemotherapy drugs for the treatment of advanced
breast cancer and consist of capecitabine (after failure of
anthracyclines and taxanes), paclitaxel (after failure of
anthracyclines), eribulin (after failure of anthracyclines
and taxanes), and vinorelbine (after failure of anthracy-
clines and taxanes) [34, 35, 37]. Capecitabine is a reason-
able first choice for the expected population, which will
consist of both ER-negative (BRCA1 mutation enriched)
and ER-positive (BRCA2 mutation enriched) tumors,
and has as an advantage that it is taken orally. We chose
to enforce a homogeneous control group with one fixed
comparator over physician’s best choice as first line
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treatment. Following recommendations of the “EMA
Guideline on the evaluation of anticancer medicinal
products in man,” we follow up patients in second line
therapy to have an early indication if first line treat-
ment has unfavorable effects on long-term survival
[46]. Physician’s best choice in second line allows for
tailoring the optimal drug out of the registered options,
based on patient characteristics and pretreatment. At
the moment no registered control regimen specifically
targets a BRCA1 or BRCA2 defect. This precludes com-
paring carboplatin-olaparib to carboplatin alone if we
only use registered choices. Crossover designs would
ultimately only provide evidence on the sequence of ap-
plying carboplatin-olaparib or capecitabine in BRCA1-
or BRCA2-mutated breast cancers but not on whether
the regimen targeting the BRCA defect is better than a
control treatment. In such a design it is also impossible
to determine whether a DNA damage-inducing regimen
in first line treatment may limit the efficacy of later
lines of therapy.
The chosen design aims to provide evidence for a clin-
ically meaningful improvement of carboplatin-olaparib
followed by olaparib monotherapy over current standard
therapy as first line treatment for BRCA1- or BRCA2-
mutated advanced breast cancer. If this improvement is
observed, the results can serve as a basis for registration
of carboplatin-olaparib followed by olaparib monother-
apy in combination with BRCA1 or BRCA2 mutation as
biomarker.
Trial status
We are currently recruiting patients for Part 1.
Additional file
Additional file 1: Revival study SPIRIT checklist. Description of the trial
protocol with the SPIRIT checklist. (DOC 122 kb)
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